摘要
目的观察分析康艾注射液联合多西他赛及泼尼松治疗骨转移激素抵抗性前列腺癌的临床疗效。方法选取于张家口市第一医院接受治疗的骨转移激素抵抗性前列腺癌患者64例进行观察研究,根据治疗方式不同分为研究组与对照组,每组32例。对照组患者给予多西他赛及泼尼松进行治疗,研究组患者在对照组治疗的基础上再联合康艾注射液进行治疗。回顾性分析2组患者的临床资料,观察2组患者治疗后的临床疗效及不良反应发生情况。结果研究组疗效总有效率明显高于对照组(P<0.05)。研究组止痛总有效率明显高于对照组(P<0.05)。治疗后,研究组骨转移病灶消退7例,14例患者转移灶显著缩小或变浅,总有效率为65.63%;对照组骨转移病灶消退2例,7例患者转移灶显著缩小或变浅,2例患者病灶同时伴有肝转移,肿瘤直径显著缩小,总有效率为34.38%。研究组病灶变化的总有效率明显高于对照组(P<0.05)。研究组患者骨髓抑制、胃肠反应、肝肾功能异常等不良反应发生率均低于对照组患者(P<0.05);研究组患者周围神经麻痹、嗜睡等不良反应发生率高于对照组患者(P<0.05)。结论康艾注射液联合多西他赛及泼尼松治疗骨转移激素抵抗性前列腺癌有较好的疗效,不良反应可耐受,康艾注射液可以明显提高患者免疫力,有效减轻患者骨痛及骨相关事件的发生,提高患者生存周期。
Objective To observe and analyze the clinical efficacy of Kang＇ai injection combined with docetaxel and prednisone in the treatment of hormone refractory prostate cancer complicated with bone metastasis. Methods Sixtyfour cases of hormone resistant prostate cancer complicated with bone metastasis treated in our hospital were equally divided into the study group and the control group according to treatment methods. Patients in the control group were treated with docetaxel and prednisone while those in the study group were additionally given Kang＇ai injection. The clinical data of the two groups of patients was retrospectively analyzed and the clinical efficacy and adverse reactions of the two groups were observed. Results The total effective rate of the study group was significantly higher than that of the control group（P〈0.05）, so was the total effective rate of pain relief（P〈0.05）. After treatment, bone metastasis lesions in the study group were reduced in seven cases, and metastasis in fourteen cases was significantly reduced or became shallower, with a total effective rate of 65.63%. In the control group, bone metastasis subsided in two cases, metastasis was significantly reduced or became shallower in seven cases, and liver metastasis occurred in two cases at the same time the, total effective rate was 34.38%. The total effective rate of shrinking tumor diameters in the study group was significantly higher than that in the control group（P〈0.05）. The incidence of adverse reactions such as myelosuppression, gastrointestinal reactions and abnormal liver and kidney function in the study group was lower than that in the control group（P〈0.05）. The incidence of adverse reactions such as peripheral nerve paralysis and drowsiness in the study group was higher than that in the control group（P〈0.05）. Conclusion Kang＇ai injection combined with docetaxel and prednisone in the treatment of bone metastatic hormone refractory prostate cancer has good curative effect, and the toxicity can be tolerated. Kang＇ai injection can obviously improve the immunity of patients, reduce the incidence of bone pain and bone related events and improve the patients＇ survival.
作者
武俊平
陈婷婷
宋文华
杨国栋
马文波
WU Junping;CHEN Tingting;SONG Wenhua;YANG Guodong;MA Wenbo(Department of Urinary Surgery, The First Hospital of Zhangjiakou, Zhangjiakou Hebei 075000, Chin)
出处
《空军医学杂志》
2018年第2期115-118,126,共5页
Medical Journal of Air Force
关键词
康艾注射液
多西他赛
泼尼松
骨转移
激素抵抗性前列腺癌
临床疗效
Kang＇ai injection
docetaxel
prednisone
bone metastasis
hormone refractory prostate cancer
clinical effect
